Tekla Life Operating Income Over Time
| HQL Stock | USD 16.78 0.09 0.53% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tekla Life Performance and Tekla Life Correlation. Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. Market participants price Tekla higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tekla Life assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.594 | Dividend Share 1.82 | Earnings Share 2.79 | Revenue Per Share | Quarterly Revenue Growth (0.70) |
Tekla Life Sciences's market price often diverges from its book value, the accounting figure shown on Tekla's balance sheet. Smart investors calculate Tekla Life's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Tekla Life's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Tekla Life Sciences and related stocks such as Cion Investment Corp, BlackRock TCP Capital, and Gladstone Capital Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CION | 25 K | 25 K | 25 K | 6.1 M | 16.3 M | (1.4 M) | 119.7 M | 85.9 M | 76.9 M | 51.8 M | (11 M) | 119.1 M | 100.1 M | 95.3 M | 34 M | 39.1 M | 58.6 M |
| TCPC | (44.7 M) | 7.1 M | 29 M | 64.4 M | 50.8 M | 120.3 M | 95.9 M | 90.6 M | 81.2 M | 30.6 M | 71.4 M | 133.8 M | 127.8 M | 154.6 M | (62.6 M) | (72 M) | (68.4 M) |
| GLAD | (92.6 K) | (3.6 M) | 35.4 M | 13.9 M | 12.3 M | 14.3 M | 20.3 M | 24.5 M | 19.9 M | (1.9 M) | 84.3 M | 32.9 M | 42.7 M | 94.7 M | 80.4 M | 92.4 M | 97.1 M |
| GIG | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (3 M) | 2.5 K | (628.8 K) | (628.8 K) | (628.8 K) | (628.8 K) | (723.1 K) | (759.2 K) |
| ECC | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 29.1 M | 40.5 M | 44.1 M | (40.1 M) | (8.7 M) | 60.9 M | 131.9 M | (87.7 M) | 118.8 M | 85.5 M | 98.3 M | 103.2 M |
| PNNT | (16.6 M) | 57.4 M | 107.1 M | 131.3 M | 16.1 M | 48.7 M | 90.1 M | 70.5 M | 17.1 M | (14.8 M) | 167.2 M | 11.9 M | (26.1 M) | 51.9 M | 35.3 M | 40.6 M | 50.8 M |
| SOR | 11.1 M | 1.9 M | 2.8 M | 1.1 M | 1.2 M | 172.5 K | 3.5 M | 48.7 M | (27.8 M) | 65.7 M | 21.2 M | 41.5 M | (27.1 M) | 16.3 M | 39.2 M | 45 M | 47.3 M |
| MCI | 37 M | 26.1 M | 26.1 M | 24.5 M | 25.6 M | 22 M | 23.8 M | 45.1 M | 10.6 M | 39 M | 15.3 M | 53.4 M | 16.7 M | 35.6 M | 37.5 M | 43.2 M | 31.7 M |
| CCAP | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | 11.8 M | 14.6 M | 8.2 M | 29.6 M | 55.4 M | 87.3 M | 16.5 M | 84.1 M | 74.7 M | 86 M | 90.2 M |
| GAIN | 6.1 M | 22 M | 17.3 M | (1.3 M) | 50.2 M | 29 M | 44.8 M | 60.7 M | 81.6 M | 3 M | 44.8 M | 118.6 M | 51.4 M | 85.3 M | 65.3 M | 75.1 M | 78.9 M |
Tekla Life Sciences and related stocks such as Cion Investment Corp, BlackRock TCP Capital, and Gladstone Capital Operating Income description
Operating Income is the amount of profit realized from Tekla Life Sciences operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Tekla Life Sciences is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Tekla Life Sciences | HQL |
Specialization | Financial Services, Financial Services |
| Business Address | 1900 Market Street, |
| Exchange | New York Stock Exchange |
USD 16.78
Check out Tekla Life Performance and Tekla Life Correlation. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Tekla Life technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.